Published in Liver Int on January 01, 2009
Spatiotemporal Scan and Age-Period-Cohort Analysis of Hepatitis C Virus in Henan, China: 2005-2012. PLoS One (2015) 1.97
Regulation of hepatic innate immunity by hepatitis C virus. Nat Med (2013) 1.93
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women. J Infect Dis (2011) 1.13
Modulation of hepatitis C virus RNA abundance and virus release by dispersion of processing bodies and enrichment of stress granules. Virology (2012) 1.10
Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One (2012) 1.09
Recommendations on hepatitis C screening for adults. CMAJ (2017) 1.07
Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs. PLoS One (2012) 1.07
Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup. Hepat Mon (2012) 0.97
Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol (2013) 0.96
Perihepatic lymphadenopathy in children with chronic viral hepatitis. J Ultrason (2015) 0.92
Mortality of patients infected with HIV in the intensive care unit (2005 through 2010): significant role of chronic hepatitis C and severe sepsis. Crit Care (2014) 0.91
Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study. PLoS One (2014) 0.90
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89
Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Ther (2012) 0.89
Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles. J Virol (2011) 0.88
Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87
Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study. Genes Immun (2015) 0.86
Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography. World J Gastroenterol (2012) 0.85
Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence (2013) 0.83
Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One (2011) 0.83
Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting. Clinicoecon Outcomes Res (2016) 0.83
Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol (2014) 0.82
PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis. Gut Liver (2016) 0.81
Mortality and morbidity among military personnel and civilians during the 1930s and World War II from transmission of hepatitis during yellow fever vaccination: systematic review. Am J Public Health (2013) 0.81
Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): an age-period-cohort analysis. CMAJ Open (2014) 0.81
The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study. Medicine (Baltimore) (2016) 0.81
Screening the anti infectivity potentials of native N- and C-lobes derived from the camel lactoferrin against hepatitis C virus. BMC Complement Altern Med (2014) 0.80
Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics (2011) 0.80
Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV. Front Immunol (2014) 0.80
Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials. Gastroenterol Res Pract (2013) 0.79
HCV monoinfection and HIV/HCV coinfection enhance T-cell immune senescence in injecting drug users early during infection. Immun Ageing (2016) 0.79
How do persistent infections with hepatitis C virus cause liver cancer? Curr Opin Virol (2015) 0.79
Genome-wide association studies--a summary for the clinical gastroenterologist. World J Gastroenterol (2009) 0.78
Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. Clinicoecon Outcomes Res (2010) 0.77
Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77
Insights into antiviral innate immunity revealed by studying hepatitis C virus. Cytokine (2015) 0.76
Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. World J Gastroenterol (2013) 0.76
Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention? PLoS One (2013) 0.76
Hepatitis C - Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial. Trials (2016) 0.76
HCV RNA Activates APCs via TLR7/TLR8 While Virus Selectively Stimulates Macrophages Without Inducing Antiviral Responses. Sci Rep (2016) 0.75
Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort. Am J Hematol (2016) 0.75
Influence of host resistance on viral adaptation: hepatitis C virus as a case study. Infect Drug Resist (2015) 0.75
Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C. World J Gastroenterol (2016) 0.75
Hepatitis C Virus Stimulates Murine CD8α-Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner. PLoS Pathog (2016) 0.75
A Meta-Analysis of the Association Between the I148M Variant of Patatin-Like Phospholipase Domain Containing 3 Gene and the Presence of Chronic Hepatitis C. Hepat Mon (2015) 0.75
Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. Infect Dis (Lond) (2015) 0.75
Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. Clin Interv Aging (2016) 0.75
Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway. BMC Infect Dis (2017) 0.75
Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030. BMC Infect Dis (2017) 0.75
Cross-Sectional Study to Determine the Prevalence of Hepatitis B and C Virus Infection in High Risk Groups in the Northeast Region of Brazil. Int J Environ Res Public Health (2017) 0.75
Does active hepatitis C virus infection increase the risk for infection due to Staphylococcus aureus? Eur J Clin Microbiol Infect Dis (2017) 0.75
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med (1989) 8.10
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med (1999) 6.50
Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA (1967) 6.36
A "NEW" ANTIGEN IN LEUKEMIA SERA. JAMA (1965) 6.21
Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science (1973) 5.82
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med (1995) 5.55
Epidemiology of hepatitis C. Hepatology (1997) 4.90
Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis (2001) 4.72
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology (1990) 4.43
Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology (1999) 4.14
Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol (1997) 4.08
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology (2001) 3.80
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med (1999) 3.38
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med (1975) 3.31
Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med (1991) 3.02
Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology (1998) 3.00
Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet (1989) 2.94
Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology (2001) 2.90
Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med (1986) 2.85
Transmissible agent in non-A, non-B hepatitis. Lancet (1978) 2.78
Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet (1974) 2.77
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology (2000) 2.67
45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med (2000) 2.66
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology (1991) 2.25
Iron and chronic viral hepatitis. Hepatology (1997) 2.18
The long-term pathological evolution of chronic hepatitis C. Hepatology (1996) 2.15
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol (2002) 2.09
Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology (2004) 2.08
Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut (2004) 1.93
Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med (1993) 1.89
Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology (2002) 1.88
Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet (1978) 1.82
Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology (1998) 1.70
Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology (2004) 1.70
Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology (2000) 1.68
Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol (2006) 1.66
Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis. Am J Gastroenterol (1984) 1.55
Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis (1996) 1.53
Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol (2005) 1.53
Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology (2001) 1.51
Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol (1992) 1.50
Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s. J Hepatol (2007) 1.50
Hepatitis C in asymptomatic blood donors. Hepatology (1997) 1.48
Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology (2008) 1.46
Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood (2003) 1.45
Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol (2002) 1.44
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol (2005) 1.33
A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol (2004) 1.33
Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol (2003) 1.32
The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med (2001) 1.30
Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis (2001) 1.30
Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol (2002) 1.26
Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat (2006) 1.26
Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology (1998) 1.26
Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver (2000) 1.25
Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol (2003) 1.24
The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology (1993) 1.24
Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology (2004) 1.23
Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat (2001) 1.23
Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood (2002) 1.22
Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol (2000) 1.19
Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology (2000) 1.12
POST-TRANSFUSION ANICTERIC HEPATITIS. N Engl J Med (1964) 1.10
Evidence for viral hepatitis other than type A or type B among persons in Costa Rica. N Engl J Med (1975) 1.10
Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology (1999) 1.07
Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? Dig Liver Dis (2000) 1.07
Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology (2001) 1.05
A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology (1977) 1.04
Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol (2006) 1.04
Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat (2002) 1.03
Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr (2007) 1.01
Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver (1993) 1.00
Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis. Ann Intern Med (1984) 0.98
Review article: chronic hepatitis C--natural history and cofactors. Aliment Pharmacol Ther (2005) 0.96
Coinfection by hepatitis B virus and hepatitis C virus. Antivir Ther (1998) 0.96
Event-biased referral can distort estimation of hepatitis C virus progression rate to cirrhosis, and of prognostic influences. J Clin Epidemiol (2007) 0.94
Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood (1997) 0.92
Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology (1998) 0.88
A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol (2003) 0.88
Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol (2001) 0.86
The natural history of childhood-acquired hepatitis C infection in patients with inherited bleeding disorders. Transfusion (2006) 0.86
Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut (2001) 0.86
Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign? Gastroenterology (2001) 0.86
The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood (2001) 0.83
Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure. Epidemiol Infect (2005) 0.81
Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis (2003) 0.79
Changes in liver histopathology in women infected with hepatitis C through contaminated anti-D immunoglobulin injections in Ireland. Eur J Gastroenterol Hepatol (1998) 0.78